Aclaris Therapeutics Inc. – Material Contracts Watch

EX-10.1

from 10-Q 18 pages Employment Agreement

12/34/56

EX-10.3

from 8-K 11 pages Aclaris Therapeutics, Inc. Restricted Stock Unit Grant Notice

12/34/56

EX-10.2

from 8-K 13 pages Aclaris Therapeutics, Inc. 2025 Equity Incentive Plan ​ Stock Option Grant Notice

12/34/56

EX-10.1

from 8-K 23 pages Aclaris Therapeutics, Inc. 2025 Equity Incentive Plan

12/34/56

EX-10.4

from 10-Q 2 pages ​ Aclaris Therapeutics, Inc. ​ Tenth Amended & Restated Non-Employee Director Compensation Policy ​

12/34/56

EX-10.3

from 10-Q 18 pages Employment Agreement

12/34/56

EX-10.28

from 10-K 14 pages Common Stock Purchase Warrant Aclaris Therapeutics, Inc

12/34/56

EX-10.27

from 10-K 10 pages ​ Certain Identified Information Has Been Omitted From This Exhibit Because It Is (I) Not Material and (II) of the Type That the Registrant Treats as Private or Confidential. “[***]” Indicates That Information Has Been Omitted. Collaboration Agreement

12/34/56

EX-10.26

from 10-K 65 pages ​ ​ ​ ​ Certain Identified Information Has Been Omitted From This Exhibit Because It Is (I) Not Material and (II) of the Type That the Registrant Treats as Private or Confidential. “[***]” Indicates That Information Has Been Omitted ​ ​ Exclusive License Agreement by and Between Biosion, Inc. and Aclaris Therapeutics, Inc. November 18, 2024 ​

12/34/56

EX-10.24

from 10-K 40 pages ​ Aclaris Therapeutics, Inc. Shares of Common Stock ($0.00001 Par Value Per Share) ​ Amended and Restated Sales Agreement

12/34/56

EX-10.21

from 10-K 17 pages Employment Agreement

12/34/56

EX-10.6

from 8-K 11 pages Aclaris Therapeutics, Inc. Restricted Stock Unit Grant Notice

12/34/56

EX-10.5

from 8-K 12 pages Aclaris Therapeutics, Inc. 2024 Inducement Plan Stock Option Grant Notice

12/34/56

EX-10.4

from 8-K 20 pages Aclaris Therapeutics, Inc. 2024 Inducement Plan Adopted by the Board of Directors: November 16, 2024

12/34/56

EX-10.3

from 8-K 18 pages Employment Agreement

12/34/56

EX-10.2

from 8-K 15 pages Registration Rights Agreement

12/34/56

EX-10.1

from 8-K 36 pages Securities Purchase Agreement

12/34/56

EX-10.1

from 10-Q 47 pages Royalty Purchase Agreement ​ ​ ​ ​ Aclaris Therapeutics, Inc. as Seller ​ ​ ​ - And - ​ ​ ​ Ocm Ip Healthcare Portfolio LP as Purchaser ​ ​ ​ ​ July 16, 2024 ​ ​

12/34/56

EX-10.22

from 10-K 3 pages ​ January 31, 2024 ​ via Email Neal Walker ​ Dear Neal: ​ This Agreement Contains the Terms of Your Position as Interim Chief Executive Officer and President (The “Interim CEO”) of Aclaris Therapeutics, Inc. (The “Company”) With an Effective Date of January 17, 2024. ​

12/34/56

EX-10.18

from 10-K 9 pages Separation Agreement, Waiver and Release

12/34/56